Intersect ENT (NSDQ:XENT) said today that it enrolled the first patient in a trial of its Ascend drug-coated sinus balloon.
The Menlo Park, Calif.-based company’s device is designed to deliver mometasone furoate directly to a person’s sinuses at the time of dilation.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT launches trial of drug-coated sinus balloon appeared first on MassDevice.
from MassDevice https://ift.tt/2UOCFTy
Cap comentari:
Publica un comentari a l'entrada